Clinical Trial Update: Bioequivalence Study With Clinical Endpoint Comparing Brinzolamide 1% Ophthalmic Suspension to Azopt® 1% Ophthalmic Suspension In the Treatment of Chronic Open Angle Glaucoma or Ocular Hypertension in Both Eyes [Phase 3]

View source ↗

Summary

Phase 3 bioequivalence study comparing brinzolamide 1% suspension to Azopt 1% suspension in chronic open-angle glaucoma or ocular hypertension completed with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glaucoma

Drugs mentioned

• Azopt 1% Ophthalmic Suspension (brinzolamide)
• Brinzolamide 1% Ophthalmic Suspension (brinzolamide)

Snippet

Sponsor: Actavis Inc. | Conditions: Glaucoma | Phase 3 | Status: COMPLETED | Results posted: 2020-03-02